Abstract
Background Numerous studies have revealed aberrant DNA methylation in esophageal squamous cell carcinoma (ESCC). However, they often focused on the partial genome, which resulted in an inadequate understanding of the shaped methylation features and the lack of available methylation markers for this disease.
Methods The current study investigated the methylation profiles between ESCC and paired normal samples using whole-genome bisulfite sequencing (WGBS) data and obtained a group of differentially methylated CpGs (DMC), differentially methylated regions (DMR), and differentially methylated genes (DMG). The DMGs were then verified in independent datasets and Sanger sequencing in our custom samples. Finally, we attempted to evaluate the performance of these genes as methylation markers for the classification of ESCC and multiple cancer types.
Results We obtained 438,558 DMCs, 15,462 DMRs, and 1,568 DMGs. The four significantly enriched gene families of DMGs were CD molecules, NKL subclass, HOXL subclass, and Zinc finger C2H2-type. The HOXL subclass homeobox genes were observed extensively hypermethylated in ESCC and nine other cancer types. The HOXL-score estimated by HOXC10 and HOXD1 methylation showed good ability in discriminating ESCC from normal samples, while the methylation of GSX1 displayed potential utility for pan-cancer detection.
Conclusions We observed widespread hypomethylation events in ESCC, and the hypermethylated HOXL subclass homeobox genes presented promising applications for the early detection of multiple cancer types.
Competing Interest Statement
Wuhan Ammunition Life-tech Company, Ltd. has applied for the patent relating to HOXD1 and GSX1. The other authors declare no conflict of interest.
Funding Statement
This work was financially supported by Medical Science and Technology Research Plan Joint Construction Project of Henan Province (2018020121).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Approval for this study was obtained from the Ethics Committee of the First Affiliated Hospital of Zhengzhou University (approval number 2020-KY-0152). All experiments were performed in accordance with relevant guidelines and regulations. Written informed consent was obtained from individual or guardian participants.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The TCGA CRC 450k data and GEO datasets are publicly available online. The samples and data generated in this study have been fully reflected in the manuscript.
List of abbreviations
- EC
- esophageal cancer
- ESCA
- esophageal adenocarcinoma
- ESCC
- esophageal squamous cell carcinoma
- DMC
- differentially methylated CpGs
- DMR
- differentially methylated regions
- DMG
- differentially methylated genes
- WGBS
- whole-genome bisulfite sequencing
- TCGA
- The Cancer Genome Atlas
- MSP
- methylation specific PCR
